Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are being investigated by the Durham VA Medical Center as a nutritional intervention for Post-Traumatic Stress Disorder (PTSD) in veterans. These polyunsaturated fatty acids are thought to exert therapeutic effects through anti-inflammatory mechanisms and modulation of neurobiological pathways associated with stress, anxiety, and mood. The clinical research focuses on evaluating the efficacy of high-dose supplementation (titrated up to 975mg EPA and 675mg DHA three times daily) on PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (CAPS), and cognitive function. This intervention represents an investigational use of a dietary supplement rather than a proprietary pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acid (Durham VA Health Care System).